Acquired platelet dysfunction with eosinophilia (APDE) is a syndrome which manifests as a transient state of platelet dysfunction in the presence of eosinophilia. The aim of this work was to study the clinical course and outcomes of children diagnosed with APDE. The hospital records of children with APDE were retrospectively reviewed and a total of 69 children were included. The mean (standard deviation) age at diagnosis was 6.9 (3.1) years. All of the patients presented with ecchymoses on the extremities, body, and face. None had serious bleeding symptoms. Platelet counts were within the normal range but all of the patients had abnormal platelet morphology by light microscopy. Parasitic infestation was found in 38% and most (87%) were treated with antiparasitic drugs. The median time from the onset of symptoms to remission was 2.6 months (95% CI 1.8-3.1). The overall complete remission rates at 3, 6, and 12 months were 61, 90, and 94%, respectively, with a median follow-up time after remission of 14.0 months (interquartile range 6.0-30.8). Neither univariate nor multivariate analysis indicated any statistically significant determinants for remission time. In our study, APDE was transient with spontaneous remission, no serious bleeding manifestations, and had a benign clinical course.

1.
Kueh YK: The syndrome of non-thrombocytopenic purpura with eosinophilia - an acquired platelet dysfunction. New Engl J Med 1982;306:365.
2.
Lackner H, Karpatkin S: On the “easy bruising” syndrome with normal platelet count: a study of 75 patients. Ann Intern Med 1975;83:190-196.
3.
Mitrakul C: Transient, spontaneous bruising with long bleeding time and normal platelet count. Am J Clin Pathol 1975;63:81-86.
4.
Suvatte V, Mahasandana C, Tanphaichitr V, Tuchinda S: Acquired platelet dysfunction with eosinophilia: study of platelet function in 62 cases. Southeast Asian J Trop Med Public Health 1979;10:358-367.
5.
Hathirat P, Bintadish P, Sasanakul W, Isarangkura P: Blood components therapy in acquired platelet dysfunction with eosinophilia: a preliminary report. Southeast Asian J Trop Med Public Health 1979;10:368-372.
6.
Hathirat P, Bintadish P, Isarangkura P, Sasanakul W, Chiewsilp P, Ratanasirivanich P: Platelet transfusion in acquired platelet dysfunction with eosinophilia. Southeast Asian J Trop Med Public Health 1982;13:220-224.
7.
Hathirat P, Isarangkura P, Pintadit P, Chuansumrit A, Mahaphan W: Immunoglobulins in acquired platelet dysfunction with eosinophilia. Southeast Asian J Trop Med Public Health 1993;24:206-209.
8.
Laosombat V, Wongchanchailert M, Sattayasevana B, Kietthubthew S, Wiriyasateinkul A: Acquired platelet dysfunction with eosinophilia in children in the south of Thailand. Platelets 2001;12:5-14.
9.
Lee AC: Unusual hematologic disease affecting Caucasian children traveling to Southeast Asia: acquired platelet dysfunction with eosinophilia. Hematol Rep 2012;4:5.
10.
Ramanathan M, Duraisamy G: Acquired platelet dysfunction with eosinophilia (APDE): an underrecognised condition. Med J Malaysia 1987;42:53-55.
11.
Chin NS, Koong PL: A study of 31 patients with easy bruising from University Hospital, Kuala Lumpur. Med J Malaysia 1990;45:325-328.
12.
Ruiz-Saez A, Sifontes LN, Feijoo R, Certad G, Arenas-Pinto A, Pocaterra L, Ferrara G, Gimenez R, Torres O, Goldstein C, Bosch N: Platelet dysfunction-eosinophilia syndrome in parasitized Venezuelan children. Am J Trop Med Hyg 2005;73:381-385.
13.
Kueh YK, Chan L, Lim BC, Wong HB: Transient non-thrombocytopenic purpura in hookworm infestation. Scand J Haematol 1983;30:174-176.
14.
Poon MC, Ng SC, Coppes MJ: Acquired platelet dysfunction with eosinophilia in white children. J Pediatr 1995;126:959-961.
15.
Lim SH, Tan CE, Agasthian T, Chew LS: Acquired platelet dysfunction with eosinophilia: review of seven adult cases. J Clin Pathol 1989;42:950-952.
16.
Maziero AM, Lorenzetti R, Donato JL, Lilla S, De Nucci G: Inhibition of human platelet aggregation by eosinophils. Life Sci 2013;93:416-422.
17.
Zahavi J, Marder VJ: Acquired “storage pool disease” of platelets associated with circulating antiplatelet antibodies. Am J Med 1974;56:883-890.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.